JTK-853, a Novel Non-Nucleoside Hepatitis C Virus Polymerase Inhibitor, Demonstrates a High Genetic Barrier to Resistance in vitro

Publisher： Karger

E-ISSN： 1423-0100|56|5|302-309

ISSN： 0300-5526

Source： Intervirology, Vol.56, Iss.5, 2013-07, pp. : 302-309

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Dasabuvir: A Non-Nucleoside Inhibitor of NS5B for the Treatment of Hepatitis C Virus Infection

By  

Reviews on Recent Clinical Trials, Vol. 9, Iss. 2, 2014-06 ,pp. : 115-123

Bentham Science Publishers

Access to resources Recommend Favorite

GSK2878175, a pan‐genotypic non‐nucleoside NS5B polymerase inhibitor, in healthy and treatment‐naïve chronic hepatitis C subjects

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 25, Iss. 1, 2018-01 ,pp. : 19-27

John Wiley & Sons Inc

Access to resources Recommend Favorite

Interactions of the hepatitis C virus protease inhibitor faldaprevir with cytochrome P450 enzymes: In vitro and in vivo correlation

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. 4, 2015-04 ,pp. : 467-477

John Wiley & Sons Inc

Access to resources Recommend Favorite

Low‐dose short‐term hepatitis B immunoglobulin with high genetic barrier antivirals: the ideal post‐transplant hepatitis B virus prophylaxis?

By  

TRANSPLANT INFECTIOUS DISEASE (ELECTRONIC), Vol. 17, Iss. 3, 2015-06 ,pp. : 329-333

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C

By  

HEPATOLOGY, Vol. 62, Iss. 2, 2015-08 ,pp. : 409-416

John Wiley & Sons Inc

Access to resources Recommend Favorite